FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma

M Dhir, MS Zenati, A Hamad, AD Singhi… - Annals of surgical …, 2018 - Springer
Background Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …
被引用次数：107 相关文章

FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.

M Dhir, MS Zenati, A Hamad, AD Singhi… - Annals of Surgical …, 2018 - europepmc.org
Background Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …
[PDF] academia.edu

[PDF][PDF] FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma

MD Mashaal Dhir, MS Zenati, HJZ MD3 III, AH Zureikat - 2018 - academia.edu
Background. Both FOLFIRINOX and gemcitabine/nabpaclitaxel (G-nP) are used increasingly
in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA). This study …

Folfirinox versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic adenocarcinoma: A propensity matched …

M Dhir, MS Zenati, A Hamad, AD Singhi, N Bahary… - 2018 - ascopubs.org
402 Background: Comparative effectiveness of FOLFIRINOX and Gemcitabine/nab-
paclitaxel (G-nP) in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …

FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma

M Dhir, MS Zenati, A Hamad, AD Singhi… - Annals of Surgical …, 2018 - search.proquest.com
Background Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …

FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma

M Dhir, MS Zenati, A Hamad… - Annals of …, 2018 - utsouthwestern.elsevierpure.com
Background: Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …

[引用][C] FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma

M Dhir, MS Zenati, A Hamad, AD Singhi… - Annals of Surgical …, 2018 - cir.nii.ac.jp
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable
and Borderline Resectable Pancreatic Head Adenocarcinoma | CiNii Research CiNii 国立 …

FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma

M Dhir, MS Zenati, A Hamad… - Annals of surgical …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …